Segment
Type of investment
Limited partnerships
Under certain circumstances, Flerie will become a limited partner in a fund. This allows Flerie to access the network, opportunities and skills of another investment company. This segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio. The segment also enables further diversification and sourcing potential.
Undisclosed fund 1
Focused on life science companies
Undisclosed fund 2
Focused on life science companies
Undisclosed fund 3
Focused on life science companies
Divested companies
Flerie encourages partnerships and M&A activity to accelerate bringing treatments to patients. When this results in an acquisition, proceeds are reallocated to the investment pool in line with our evergreen strategy.
Wilson Therapeutics
Wilson Therapeutics was a biopharmaceutical company, based in Stockholm, Sweden, developing novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics' product, WTX101, was in Phase 3 development as a novel treatment for Wilson disease when it was acquired by Alexion in 2018.